ERBB2 and breast carcinoma: The expression of HER2 proto-oncogene in normal breast epithelial cells that gives rise to a 185 kDa trans-membrane glycoprotein and its overexpression, found in 20%–30% of human breast cancers, correlates with more aggressive tumors and a poorer prognosis [6,7].